(Q33913894)

30 July 2017

1 reference

title

Adaptive control methods for the dose individualisation of anticancer agents (English)

1 reference

30 July 2017

Rousseau A

1

1 reference

30 July 2017

Marquet P

2

1 reference

30 July 2017

Debord J

3

1 reference

30 July 2017

Sabot C

4

1 reference

30 July 2017

Lachâtre G

5

1 reference

30 July 2017

1 April 2000

1 reference

Clinical Pharmacokinetics

30 July 2017

1 reference

30 July 2017

38

1 reference

30 July 2017

315-353

1 reference

30 July 2017

4

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200038040-00003

30 July 2017

0 references

cites work

Predicting etoposide toxicity: relationship to organ function and protein binding

1 reference

12 December 2020

Pharmacokinetic study of active ultrafiltrable platinum during a 5-day course of continuous constant flow infusion of cisplatin with modification of the dosage

1 reference

12 December 2020

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

1 reference

12 December 2020

Methodological issues in pharmacokinetic-pharmacodynamic modelling.

1 reference

12 December 2020

Doxorubicin and doxorubicinol: intra- and inter-individual variations of pharmacokinetic parameters

1 reference

12 December 2020

Pharmacokinetic optimisation of cancer chemotherapy. Effect on outcomes

1 reference

12 December 2020

Long-term survivors of advanced neuroblastoma with MYCN amplification: A report of 19 patients surviving disease-free for more than 66 months

1 reference

12 December 2020

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

12 December 2020

A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity

1 reference

12 December 2020

Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters

1 reference

12 December 2020

Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods.

1 reference

12 December 2020

A Bayesian dosing method for carboplatin given by continuous infusion for 120 h.

1 reference

12 December 2020

A limited sampling method for estimation of the carboplatin area under the curve.

1 reference

12 December 2020

Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).

1 reference

12 December 2020

Clinical pharmacokinetics of topotecan

1 reference

12 December 2020

Use of adaptive control with feedback to individualize suramin dosing

1 reference

12 December 2020

Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.

1 reference

12 December 2020

A limited sampling strategy for the study of pirarubicin pharmacokinetics in humans

1 reference

12 December 2020

Bayesian forecasting in paediatric populations.

1 reference

12 December 2020

The concentration-effect relationship of quinine-induced hearing impairment

1 reference

12 December 2020

A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage.

1 reference

12 December 2020

Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer.

1 reference

12 December 2020

Preliminary phase I study of 4'-epi-adriamycin

1 reference

12 December 2020

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

1 reference

12 December 2020

Escalating teniposide systemic exposure to increase dose intensity for pediatric cancer patients.

1 reference

12 December 2020

Escalating systemic exposure of continuous infusion topotecan in children with recurrent acute leukemia.

1 reference

12 December 2020

Bayesian estimation and prediction of clearance in high-dose methotrexate infusions.

1 reference

12 December 2020

Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.

1 reference

12 December 2020

Clinical pharmacokinetics of vinorelbine

1 reference

12 December 2020

Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients

1 reference

12 December 2020

Relationship between fluorouracil systemic exposure and tumor response and patient survival

1 reference

12 December 2020

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugs

1 reference

12 December 2020

Liquid chromatography-mass spectrometry: potential in forensic and clinical toxicology

1 reference

12 December 2020

Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance

1 reference

12 December 2020

Pharmacokinetics and metabolism of pirarubicin in advanced cancer patients

1 reference

12 December 2020

Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer

1 reference

12 December 2020

A limited sampling method for estimation of the etoposide area under the curve

1 reference

12 December 2020

Evaluation of two dose individualisation methods for carboplatin.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of long-term continuous-infusion doxorubicin

1 reference

12 December 2020

Pharmacodynamics in cancer therapy

1 reference

12 December 2020

Dosage predictions in high-dose methotrexate infusions. Part 2: Bayesian estimation of methotrexate clearance.

1 reference

12 December 2020

Pharmacokinetics of anticancer drugs in children

1 reference

12 December 2020

Role of population pharmacokinetics in drug development. A pharmaceutical industry perspective

1 reference

12 December 2020

Bayesian pharmacokinetic estimation of vinorelbine in non-small-cell lung cancer patients.

1 reference

12 December 2020

Efficient sampling strategies for forecasting pharmacokinetic parameters of irinotecan (CPT-11): implication for area under the concentration-time curve monitoring

1 reference

12 December 2020

Influence of biological variables upon pharmacokinetic parameters of intramuscular methotrexate in rheumatoid arthritis.

1 reference

12 December 2020

Validity of linear regression in method comparison studies: is it limited by the statistical model or the quality of the analytical input data?

1 reference

12 December 2020

Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells

1 reference

12 December 2020

Adaptive control of etoposide administration: impact of interpatient pharmacodynamic variability.

1 reference

12 December 2020

Impact of cyclophosphamide on relationships between carboplatin exposure and response or toxicity when used in the treatment of advanced ovarian cancer

1 reference

12 December 2020

Pharmacodynamic monitoring of cancer chemotherapy: childhood acute lymphoblastic leukemia as a model

1 reference

12 December 2020

Alternative approaches for Phase I studies of anticancer drugs: a role for therapeutic drug monitoring

1 reference

12 December 2020

Plasma free platinum pharmacokinetics in patients treated with high dose carboplatin

1 reference

12 December 2020

[Individualization of the dosage of high-dose methotrexate by assaying plasma concentration. Therapeutic value in osteogenic sarcoma]

1 reference

12 December 2020

Pharmacokinetics and acute renal effects of continuously infused carboplatin

1 reference

12 December 2020

5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer

1 reference

12 December 2020

Clinical pharmacokinetics-pharmacodynamics of anticancer drugs

1 reference

12 December 2020

A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression

1 reference

12 December 2020

Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia

1 reference

12 December 2020

Suramin in hormone-refractory metastatic prostate cancer: a drug with limited efficacy

1 reference

12 December 2020

CPT-11: population pharmacokinetic model and estimation of pharmacokinetics using the Bayesian method in patients with lung cancer.

1 reference

12 December 2020

Prospective evaluation of a model for predicting etoposide plasma protein binding in cancer patients.

1 reference

12 December 2020

A limited sampling procedure for estimating adriamycin pharmacokinetics in cancer patients

1 reference

12 December 2020

Development and validation of a limited sampling strategy for 5-fluorouracil given by bolus intravenous administration

1 reference

12 December 2020

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II study

1 reference

12 December 2020

Pharmacokinetics and metabolism of Taxotere (docetaxel).

1 reference

12 December 2020

Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients

1 reference

12 December 2020

Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study

1 reference

12 December 2020

Dosage predictions in high-dose methotrexate infusions. Part 1: Evaluation of the classic test-dose protocol.

1 reference

12 December 2020

Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. Identification of a relation between concentration and effect

1 reference

12 December 2020

Can pharmacokinetic monitoring improve clinical use of fluorouracil?

1 reference

12 December 2020

Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks.

1 reference

12 December 2020

Early clinical studies with cis-diammine-1,1-cyclobutane dicarboxylate platinum II.

1 reference

12 December 2020

[Bayesian estimation of pharmacokinetic parameters of etoposide]

1 reference

12 December 2020

Methotrexate pharmacokinetics and prognosis in osteosarcoma.

1 reference

12 December 2020

A limited-sampling strategy for estimation of etoposide pharmacokinetics in cancer patients.

1 reference

12 December 2020

Population pharmacokinetics

1 reference

12 December 2020

Forecasting individual pharmacokinetics

1 reference

12 December 2020

Pharmacokinetics of continuous infusion of methotrexate and teniposide in pediatric cancer patients.

1 reference

12 December 2020

Individualized dosages of chemotherapy as a strategy to improve response for acute lymphocytic leukemia

1 reference

12 December 2020

Population and Bayesian pharmacokinetics in oncology

1 reference

12 December 2020

Predicting individual phenytoin dosage

1 reference

12 December 2020

Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea

1 reference

12 December 2020

Suramin: an anticancer drug with a unique mechanism of action.

1 reference

12 December 2020

Pharmacological considerations in high-dose chemotherapy

1 reference

12 December 2020

Phase I and pharmacokinetics study of topotecan, a new topoisomerase I inhibitor

1 reference

12 December 2020

Clinical pharmacokinetics of etoposide during 120 hours continuous infusions in solid tumours

1 reference

12 December 2020

Clinical pharmacodynamics of anticancer drugs: a basis for extending the concept of dose-intensity

1 reference

12 December 2020

Population pharmacokinetics. A regulatory perspective.

1 reference

12 December 2020

Comparison of 2- and 3-compartment models for the Bayesian estimation of methotrexate pharmacokinetics.

1 reference

12 December 2020

Topotecan. A review of its potential in advanced ovarian cancer

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion topotecan in children: systemic exposure predicts hematologic toxicity

1 reference

12 December 2020

A population pharmacokinetic model for docetaxel (Taxotere): model building and validation

1 reference

12 December 2020

Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum

1 reference

12 December 2020

Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Topotecan in platinum- and paclitaxel-resistant ovarian cancer

1 reference

12 December 2020

Phase I study of pharmacologically based dosing of carboplatin with filgrastim support in women with epithelial ovarian cancer

1 reference

12 December 2020

Pharmacokinetic studies in cancer chemotherapy: usefulness in clinical practice

1 reference

12 December 2020

Altered etoposide pharmacokinetics and time to engraftment in pediatric patients undergoing autologous bone marrow transplantation

1 reference

12 December 2020

Phase I and clinical evaluation of a pharmacologically guided regimen of suramin in patients with hormone-refractory prostate cancer

1 reference

12 December 2020

Polyglutamation of methotrexate. Is methotrexate a prodrug?

1 reference

12 December 2020

Carboplatin pharmacokinetics in children: the development of a pediatric dosing formula. The United Kingdom Children's Cancer Study Group

1 reference

12 December 2020

Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study

1 reference

12 December 2020

New techniques in the pharmacokinetic analysis of cancer drugs. III. Nuclear magnetic resonance.

1 reference

12 December 2020

Model-based, goal-oriented, individualised drug therapy. Linkage of population modelling, new 'multiple model' dosage design, bayesian feedback and individualised target goals

1 reference

12 December 2020

Analytical goals in therapeutic drug monitoring

1 reference

12 December 2020

Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach.

1 reference

12 December 2020

Pharmacokinetics of high-dose methotrexate in adult osteogenic sarcoma.

1 reference

12 December 2020

Clinical pharmacokinetics of irinotecan

1 reference

12 December 2020

Graphical interpretation of analytical data from comparison of a field method with reference method by use of difference plots.

1 reference

12 December 2020

A limited-sampling method for evaluation of the area under the curve of ultrafilterable carboplatin in children

1 reference

12 December 2020

Cisplatin neurotoxicity: the relationship between dosage, time, and platinum concentration in neurologic tissues, and morphologic evidence of toxicity

1 reference

12 December 2020

Clinical impact of pharmacokinetically-guided dose adaptation of 5-fluorouracil: results from a multicentric randomized trial in patients with locally advanced head and neck carcinomas

1 reference

12 December 2020

Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial

1 reference

12 December 2020

Pharmacokinetics of vinorelbine in patients with liver metastases.

1 reference

12 December 2020

Analysis of pharmacokinetic data using parametric models--1: Regression models

1 reference

12 December 2020

Population pharmacokinetics of total and unbound etoposide.

1 reference

12 December 2020

Modeling interpatient pharmacodynamic variability of etoposide.

1 reference

12 December 2020

Population pharmacokinetics: theory and practice

1 reference

12 December 2020

The use of population pharmacokinetics in drug development

1 reference

12 December 2020

Some suggestions for measuring predictive performance

1 reference

12 December 2020

Induction of transformed cells to terminal differentiation and the modulation of gene expression

1 reference

12 December 2020

A limited sampling strategy for cyclophosphamide pharmacokinetics.

1 reference

12 December 2020

A sequential Bayesian algorithm for dose individualisation of carboplatin

1 reference

12 December 2020

Is there an optimal time to administer methotrexate in the treatment of rheumatoid arthritis?

1 reference

12 December 2020

Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3, and 5 in patients with solid tumors

1 reference

12 December 2020

Phase I study of CPT-11 and etoposide in patients with refractory solid tumors

1 reference

12 December 2020

Bayesian estimation of doxorubicin pharmacokinetic parameters

1 reference

12 December 2020

Methotrexate toxicity: Correlation with duration of administration, plasma levels, dose and excretion pattern

1 reference

12 December 2020

Phase II trial of suramin in patients with advanced renal cell carcinoma: treatment results, pharmacokinetics, and tumor growth factor expression

1 reference

12 December 2020

General versus subpopulation values in Bayesian prediction of aminoglycoside pharmacokinetics in hematology-oncology patients.

1 reference

12 December 2020

Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients

1 reference

12 December 2020

[Pharmacokinetics in phase IV studies for the preview of a therapeutic protocol]

1 reference

12 December 2020

Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals

1 reference

12 December 2020

Effectiveness of carboplatin, etoposide, and bleomycin combination chemotherapy in good-prognosis metastatic testicular nonseminomatous germ cell tumors

1 reference

12 December 2020

Modelling of individual pharmacokinetics for computer-aided drug dosage

1 reference

12 December 2020

Software for population pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Clinical pharmacokinetics and dose optimisation of carboplatin.

1 reference

12 December 2020

Prediction of carboplatin clearance from standard morphological and biological patient characteristics

1 reference

12 December 2020

Clinical pharmacodynamics of continuous-infusion etoposide

1 reference

12 December 2020

Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity

1 reference

12 December 2020

Dose monitoring of 5-fluorouracil in patients with colorectal or head and neck cancer--status of the art.

1 reference

12 December 2020

Dosage adjustment of high-dose methotrexate using Bayesian estimation: a comparative study of two different concentrations at the end of 8-h infusions.

1 reference

12 December 2020

Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen

1 reference

12 December 2020

Carboplatin dosage: prospective evaluation of a simple formula based on renal function

1 reference

12 December 2020

Comparison of the Akaike Information Criterion, the Schwarz criterion and the F test as guides to model selection.

1 reference

12 December 2020

Predicting effective drug concentrations for individual patients. Determinants of pharmacodynamic variability

1 reference

12 December 2020

Etoposide dosage and pharmacodynamics

1 reference

12 December 2020

Differences in teniposide disposition and pharmacodynamics in patients with newly diagnosed and relapsed acute lymphocytic leukemia

1 reference

12 December 2020

Population Pharmacokinetics/Dynamics*

1 reference

12 December 2020

Phase I Study and Pharmacokinetics of CPT-11 With 5-Day Continuous Infusion

1 reference

12 December 2020

Chronopharmacokinetics. Current status

1 reference

12 December 2020

Bayesian parameter estimation and population pharmacokinetics

1 reference

12 December 2020

Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer

1 reference

12 December 2020

Simple Bayesian analysis in clinical trials: a tutorial.

1 reference

12 December 2020

Relation of systemic exposure to unbound etoposide and hematologic toxicity

1 reference

12 December 2020

A sensitive and reproducible HPLC assay for doxorubicin and pirarubicin

1 reference

12 December 2020

A pharmacokinetic and pharmacodynamic study of the new anthracycline pirarubicin in breast cancer patients

1 reference

12 December 2020

Limited-sampling models for estimation of the carboplatin area under the curve.

1 reference

12 December 2020

Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients

1 reference

12 December 2020

Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation

1 reference

12 December 2020

Clinical pharmacokinetics of suramin in patients with HTLV-III/LAV infection.

1 reference

12 December 2020

Optimal sampling strategies for bayesian estimation of docetaxel (Taxotere) clearance.

1 reference

12 December 2020

Factors affecting epirubicin pharmacokinetics and toxicity: evidence against using body-surface area for dose calculation

1 reference

12 December 2020

Adaptive control with feedback strategies for suramin dosing.

1 reference

12 December 2020

Phase I/pharmacokinetic study of topotecan by 24-hour continuous infusion weekly

1 reference

12 December 2020

Practical treatment guide for dose individualisation in cancer chemotherapy

1 reference

12 December 2020

Etoposide pharmacokinetics and pharmacodynamics after acute and chronic exposure to cisplatin

1 reference

12 December 2020

High-dose methotrexate: Preliminary evaluation of a pharmacokinetic approach

1 reference

12 December 2020

Dependence of the cytostatic effect of adriamycin on drug concentration and exposure time in vitro

1 reference

12 December 2020

Use of Plasma Pharmacokinetics to Predict and Prevent Methotrexate Toxicity

1 reference

12 December 2020

Phase I clinical and pharmacokinetic study of a 14-day infusion of etoposide in patients with lung cancer

1 reference

12 December 2020

Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer

1 reference

12 December 2020

Limited sampling models for doxorubicin pharmacokinetics

1 reference

12 December 2020

Individualizing drug dosage regimens: roles of population pharmacokinetic and dynamic models, Bayesian fitting, and adaptive control

1 reference

12 December 2020

Pharmacodynamics of three daily infusions of etoposide in patients with extensive-stage small-cell lung cancer

1 reference

12 December 2020

Indirect-response model for the time course of leukopenia with anticancer drugs.

1 reference

12 December 2020

Optimal sampling times for pharmacokinetic experiments

1 reference

12 December 2020

A limited sampling method to estimate methotrexate pharmacokinetics in patients with rheumatoid arthritis using a Bayesian approach and the population data modeling program P-PHARM.

1 reference

12 December 2020

Increased relative effectiveness of doxorubicin against slowly proliferating sarcoma 180 cells after prolonged drug exposure

1 reference

12 December 2020

Clinical pharmacokinetics in the 21st century. Does the evidence support definitive outcomes?

1 reference

12 December 2020

10.2165/00003088-200038040-00003

Identifiers

DOI

1 reference

Dimensions Publication ID

30 July 2017

0 references

1 reference